Lineage Cell Therapeutics, Inc. (LCTX)
0.8308
+0.01
(+1.32%)
USD |
NYAM |
Nov 20, 09:40
Lineage Cell Therapeutics Free Cash Flow : -26.46M for Sept. 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| September 30, 2026 | -26.46M |
| June 30, 2026 | -24.39M |
| March 31, 2026 | -22.59M |
| December 31, 2025 | -19.44M |
| September 30, 2025 | -20.88M |
| June 30, 2025 | -23.15M |
| March 31, 2025 | -22.82M |
| December 31, 2024 | -23.66M |
| September 30, 2024 | -23.06M |
| June 30, 2024 | -22.33M |
| March 31, 2024 | -23.63M |
| December 31, 2023 | -29.24M |
| September 30, 2023 | -31.42M |
| June 30, 2023 | -32.01M |
| March 31, 2023 | -32.64M |
| December 31, 2022 | 0.646M |
| September 30, 2022 | 2.914M |
| June 30, 2022 | 3.764M |
| March 31, 2022 | 5.378M |
| December 31, 2021 | -23.92M |
| September 30, 2021 | -23.56M |
| June 30, 2021 | -23.52M |
| March 31, 2021 | -22.22M |
| December 31, 2020 | -19.82M |
| September 30, 2020 | -19.68M |
| Date | Value |
|---|---|
| June 30, 2020 | -22.32M |
| March 31, 2020 | -27.94M |
| December 31, 2019 | -32.39M |
| September 30, 2019 | -33.68M |
| June 30, 2019 | -33.67M |
| March 31, 2019 | -31.24M |
| December 31, 2018 | -32.30M |
| September 30, 2018 | -31.55M |
| June 30, 2018 | -32.18M |
| March 31, 2018 | -34.07M |
| December 31, 2017 | -31.84M |
| September 30, 2017 | -35.01M |
| June 30, 2017 | -36.27M |
| March 31, 2017 | -38.00M |
| December 31, 2016 | -44.85M |
| September 30, 2016 | -50.55M |
| June 30, 2016 | -54.24M |
| March 31, 2016 | -55.60M |
| December 31, 2015 | -49.88M |
| September 30, 2015 | -44.04M |
| June 30, 2015 | -39.66M |
| March 31, 2015 | -38.19M |
| December 31, 2014 | -39.34M |
| September 30, 2014 | -39.17M |
| June 30, 2014 | -38.13M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Curis, Inc. | -30.77M |
| Armata Pharmaceuticals, Inc. | -26.86M |
| Voyager Therapeutics, Inc. | -109.83M |
| Black Diamond Therapeutics, Inc. | -33.32M |
| Invivyd, Inc. | -134.11M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -5.62M |
| Cash from Investing (Quarterly) | -5.147M |
| Cash from Financing (Quarterly) | -0.023M |
| Free Cash Flow Per Share (Quarterly) | -0.022 |
| Free Cash Flow to Equity (Quarterly) | -5.424M |
| Free Cash Flow to Firm (Quarterly) | -5.694M |
| Free Cash Flow Yield | -12.59% |